MYRELEZ

This brand name is authorized in Estonia, Finland, Ireland, Lithuania, Poland

Active ingredients

The drug MYRELEZ contains one active pharmaceutical ingredient (API):

1 Lanreotide
UNII IEU56G3J9C - LANREOTIDE ACETATE

Lanreotide is an octapeptide analogue of natural somatostatin. Like somatostatin, lanreotide is an inhibitor of various endocrine, neuroendocrine, exocrine and paracrine functions.

Read about Lanreotide

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
MYRELEZ Solution for injection Health Products Regulatory Authority (IE) MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
H01CB03 Lanreotide H Systemic hormonal preparations, excl. Sex hormones and insulins → H01 Pituitary and hypothalamic hormones and analogues → H01C Hypothalamic hormones → H01CB Somatostatin and analogues
Discover more medicines within H01CB03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: EE Ravimiamet Identifier(s): 1791154, 1791165, 1791176, 1833768, 1833779, 1833780
Country: FI Lääkealan turvallisuus- ja kehittämiskeskus Identifier(s): 392697, 449026, 549549
Country: LT Valstybinė vaistų kontrolės tarnyba Identifier(s): 1092652, 1092653, 1092654, 1092655, 1092656, 1092657
Country: PL Rejestru Produktów Leczniczych Identifier(s): 100418950, 100418966, 100418972

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.